Until now, only two reversible LSD1 inhibitors CC-90011 and SP-2577 entered the clinical trials for treatment of advanced cancers and extensive-stage SCLC alone or combined with other antitumor drugs (41). Here, KDM1A is linked to small cell lung carcinoma.